Finalized Consent Decree For Allston Largely In Line With Genzyme's Expectations

Biotech will pay an upfront disgorgement of $175 million from past profits on drugs made at Allston; must transfer all fill/finish out of troubled facility by end of November.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet